Bolt Total Current Liabilities from 2010 to 2024
| BOLT Stock | USD 0.64 0.01 1.59% |
Total Current Liabilities | First Reported 2019-12-31 | Previous Quarter 17.9 M | Current Value 18.1 M | Quarterly Volatility 5.2 M |
Check Bolt Biotherapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Bolt Biotherapeutics' main balance sheet or income statement drivers, such as Net Interest Income of 6.5 M, Interest Income of 6.5 M or Depreciation And Amortization of 2.5 M, as well as many indicators such as Price To Sales Ratio of 5.11, Dividend Yield of 0.0 or PTB Ratio of 0.39. Bolt financial statements analysis is a perfect complement when working with Bolt Biotherapeutics Valuation or Volatility modules.
Bolt | Total Current Liabilities |
Latest Bolt Biotherapeutics' Total Current Liabilities Growth Pattern
Below is the plot of the Total Current Liabilities of Bolt Biotherapeutics over the last few years. Total Current Liabilities is an item on Bolt Biotherapeutics balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of Bolt Biotherapeutics are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. It is the total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations. Bolt Biotherapeutics' Total Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Bolt Biotherapeutics' overall financial position and show how it may be relating to other accounts over time.
| Total Current Liabilities | 10 Years Trend |
|
Total Current Liabilities |
| Timeline |
Bolt Total Current Liabilities Regression Statistics
| Arithmetic Mean | 8,378,186 | |
| Geometric Mean | 5,545,795 | |
| Coefficient Of Variation | 94.78 | |
| Mean Deviation | 6,747,823 | |
| Median | 2,755,000 | |
| Standard Deviation | 7,940,700 | |
| Sample Variance | 63.1T | |
| Range | 20.4M | |
| R-Value | 0.83 | |
| Mean Square Error | 21.1T | |
| R-Squared | 0.69 | |
| Significance | 0.0001 | |
| Slope | 1,474,098 | |
| Total Sum of Squares | 882.8T |
Bolt Total Current Liabilities History
About Bolt Biotherapeutics Financial Statements
Bolt Biotherapeutics shareholders use historical fundamental indicators, such as Total Current Liabilities, to determine how well the company is positioned to perform in the future. Although Bolt Biotherapeutics investors may analyze each financial statement separately, they are all interrelated. The changes in Bolt Biotherapeutics' assets and liabilities, for example, are also reflected in the revenues and expenses on on Bolt Biotherapeutics' income statement. Understanding these patterns can help investors time the market effectively. Please read more on our fundamental analysis page.
| Last Reported | Projected for Next Year | ||
| Total Current Liabilities | 20.5 M | 16.1 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Bolt Stock Analysis
When running Bolt Biotherapeutics' price analysis, check to measure Bolt Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bolt Biotherapeutics is operating at the current time. Most of Bolt Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bolt Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bolt Biotherapeutics' price. Additionally, you may evaluate how the addition of Bolt Biotherapeutics to your portfolios can decrease your overall portfolio volatility.